Status and phase
Conditions
Treatments
About
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
Full description
The aim of this study is to include 40 patients with middle-advanced Hepatocellular Carcinoma .These patients were randomly allocated to TACE treatment group or TACE+Anlotinib treatment group.The treatment effectiveness, local tumor control and survival outcome between the two groups were compared.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
5.18~75 years old; ECOG PS score: 0-1 points; expected survival period is more than 3 months.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Guoliang Shao
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal